

SEP 28 2005 11:20AM

GW GLOBAL R&D IS

RECEIVED
CENTRAL FAX CENTER

NO. 9774 P. 1

SEP 28 2005

FAX



GlaxoSmithKline

To Attn: Examiner Janet L. COPPINS Group 1626

Company USPTO

Fax 571-273-8300

From Johnie Jones

Tel (919) 483-7867; Facsimile: (919) 483-5730

E-mail Johnie.X.Jones@gsk.com

Date September 28, 2005 Pages including cover 4

Subject Response to Notice of Non-Compliant Amendment

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel: 919 483 2100
www.gsk.com

Re: Application of: David Gene BARRETT, et al.
U.S. Serial No.: 10/510,469
Filed: October 7, 2004
Title: *Derivatives of 1-(oxoaminoacetyl) pentylcarbamate
as cathepsin k inhibitors for the treatment of bone loss*
Attorney Docket No. PU4724USw

Attached:

1. Transmittal Form with Certificate of Transmission by FAX
2. Amendment in Response to Notice of Non-Compliant Amendment

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

SEP 28 2005 11:21AM

GW GLOBAL R&D IS

RECEIVED
CENTRAL FAX CENTER

NO. 9774 P. 2

SEP 28 2005

PTO/SB/21 (09-04)

Doc

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/510,469
	Filing Date	October 7, 2004
	First Named Inventor	David Gene BARRETT
	Art Unit	1626
	Examiner Name	Janet L. COPPINS
Total Number of Pages in This Submission	Attorney Docket Number	PU4724USW

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD. Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks Applicants believe that no fee is required for this submission. However, the Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	GlaxoSmithKline	
Signature	<i>Kathryn L. Coulter</i>	
Printed name	Kathryn L. Coulter	
Date	September 28, 2005	Reg. No. 45,889

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the		
Signature	<i>Johnnie Jones</i>	
Typed or printed name	Johnnie Jones	Date September 28, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SEP 28 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : David Gene Barrett, *et al.*
Application No. : 10/510,469
Filing Date : October 7, 2004
Title : *Derivatives of*
1-(Oxoaminoacetylopentyl)carbamate as
Cathepsin K Inhibitors for Treatment of Bone Loss
Group /Art Unit. : 1626
Examiner : Janet L. COPPINS
Docket No. : PU4724USw

Mail Stop Amendment
Commissioner for Patents
Washington, DC 20231

RESPONSE TO NOTICE OF NON-COMPLIANT
AMENDMENT (37 C.F.R. 1.121)

Sir:

This communication is in response to the Notice of Non-Compliant Amendment dated September 16, 2005. According to the Notice, Applicants' amendment mailed October 7, 2004 is non-complaint because the new paragraph listed under the "Amendments to the Specification" was underlined. In response to the notice, Applicants submit a substitute sheet for page 2 of the Preliminary Amendment. In the substitute sheet, the paragraph to be inserted is not underlined.

Respectfully submitted,



Kathryn L. Coulter
Agent for Applicant
Registration No. 45,889

Date: September 28, 2005
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1467
Facsimile: 919-483-5730

OFFICIAL ACTION FRONT SHEET

The following details have been produced directly from the Database.
Please check the due dates, initial below and RETURN THIS SHEET TO THE ADMIN
FOR DOCKETING.

IPMaster (v1.6.1) - [Patent 1 of 2]

Records Utilities Tools Help

Case No: PU4724
Country: United States
Case Type: Regular
Relation Type: Original Filing
Filing Type: Patent Cooperation Treaty
Filing Number:

Attorney: Kathryn L. COULTER
Agent:
Client/Division: Pharmaceuticals
Applicant: SMITHKLINE BEECHAM CORP
External Source:

CHEMICAL COMPOUNDS

Ext. Filing Date	Related Id	Internal Title	Text	Priority	Applicants	Filing Title
Filing Date	Related Party Info	Actions	Desc and Comments	Expenses	Inventors	Other No
Action	Action Due Date	Taken Date	Deadline Date	Completed Date	Action Notes	
First Declaration due				07-Oct-2004		
Information disclosure				07-Oct-2004		
FILE IN US 30TH	10-Oct-2004			07-Oct-2004		
Non-compliant Amendment	18-Oct-2005		16-Mar-2006			
Last Day	16-Mar-2006		16-Mar-2006			
Status Inquiry Due	16-Sep-2008					

Created: 10-Sep-2004 | Updated: 20-Sep-2005 15:13:51 | By: jcd36266

DUE DATE CHECKED (ATTORNEY OR SECRETARY) _____

ACTION TAKEN DATE _____
(FOR US RESPONSES & RULE 51(6))

COMPLETED DATE _____
(DATE RESPONSE MAILED)

SPECIAL INSTRUCTIONS TO ADMIN:

☐ CASE ABANDONED

(DATE OF ABANDONMENT)

(PLEASE ATTACH A COPY OF THE ABANDONMENT LETTER FOR ADMIN RECORDS.
THANK YOU)

☐ EXTENSION OF TIME REQUESTED

NUMBER OF MONTHS

☐ DIARY DATE TO BE SIGNED OFF

ATTORNEY INITIALS